Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial.
Saved in:
| Title: | Anakinra or tocilizumab in patients admitted to hospital with severe covid-19 at high risk of deterioration (IMMCoVA): A randomized, controlled, open-label trial. |
|---|---|
| Authors: | Sundén-Cullberg, Jonas1,2 (AUTHOR) jonas.sunden-cullberg@ki.se, Chen, Puran3 (AUTHOR), Häbel, Henrike4 (AUTHOR), Skorup, Paul5 (AUTHOR), Janols, Helena5 (AUTHOR), Rasmuson, Johan6 (AUTHOR), Niward, Katarina7 (AUTHOR), Östholm Balkhed, Åse7 (AUTHOR), Chatzidionysiou, Katerina8 (AUTHOR), Asgeirsson, Hilmir1,2 (AUTHOR), Blennow, Ola1,2 (AUTHOR), Parke, Åsa1,2 (AUTHOR), Svensson, Anna-Karin1,2 (AUTHOR), Muvva, Jagadeeswara Rao3 (AUTHOR), Ljunggren, Hans-Gustav3 (AUTHOR), Horne, Anna-Carin9 (AUTHOR), Ådén, Ulrika10 (AUTHOR), Henter, Jan-Inge11 (AUTHOR), Sönnerborg, Anders1,12 (AUTHOR), Vesterbacka, Jan1,2 (AUTHOR) |
| Source: | PLoS ONE. 12/29/2023, Vol. 18 Issue 12, p1-15. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
